{
    "title": "GSK's oncology business suffers fresh blow with Zejula setback",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11417215/GSKs-oncology-business-suffers-fresh-blow-Zejula-setback.html",
    "date": "2022-11-11",
    "keywords": [
        "cancer",
        "use",
        "zejula",
        "drug",
        "gsk",
        "chemotherapy",
        "company",
        "bay",
        "therapy",
        "secondline",
        "setting",
        "news",
        "setback",
        "blood",
        "afternoon",
        "response",
        "analyst",
        "grover",
        "pushkala",
        "treatment",
        "study",
        "approval",
        "class",
        "survival",
        "indication",
        "trading",
        "comment",
        "friday",
        "option",
        "portfolio",
        "week",
        "monday",
        "blenrep",
        "question",
        "family",
        "parp",
        "lynparza",
        "clovis",
        "oncologys",
        "safety",
        "september",
        "move",
        "consultation",
        "food",
        "administration",
        "fda",
        "line",
        "effect",
        "november",
        "emergence",
        "key",
        "recurrence",
        "tube",
        "tumour",
        "meeting",
        "october",
        "request",
        "zejulas",
        "firstline",
        "priority",
        "imposition",
        "restriction",
        "spokesperson",
        "change",
        "acquisition",
        "specialist",
        "tesaro",
        "total",
        "quarter",
        "field",
        "london",
        "aripaka",
        "bengaluru",
        "editing",
        "sitholematarise"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}